Systematic Review of Clozapine Cardiotoxicity (original) (raw)

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry. 1996;57 Suppl 9:35–40.
    PubMed Google Scholar
  2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.
    Article CAS PubMed Google Scholar
  3. Baldessarini RJ, Frankenburg FR. Clozapine—a novel antipsychotic agent. N Engl J Med. 1991;324:746–54.
    Article CAS PubMed Google Scholar
  4. Curto M, Comparelli A, Ciavarella GM, et al. Impairment of left ventricular function early in treatment with clozapine: preliminary study. Int Clin Psychopharmacol. 2015;30:282–9.
    PubMed Google Scholar
  5. Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry. 1998;59 Suppl 3:44–8.
    CAS PubMed Google Scholar
  6. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91.
    Article CAS PubMed Google Scholar
  7. Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: meta-analysis. Schizophr Res. 2005;73:139–45.
    Article PubMed Google Scholar
  8. Baldessarini RJ. Chemotherapy in psychiatry. 3rd ed. New York: Springer; 2013.
    Book Google Scholar
  9. Clozaril® (clozapine) tablets [product monograph]. Novartis Pharmaceuticals Corporation, Basel, Switzerland, 2014.
  10. AIFA Farmaciemedici.it [Internet homepage; updated 6 Jun 2014]. Available from: http://www.farmaciemedici.it/farmaci/bugiardino/leponex/aifa/. Accessed 22 Sep 2015.
  11. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005;25:32–41.
    Article CAS PubMed Google Scholar
  12. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132:231–40. The study highlights the importance and the reasons of the possible underestimation of clozapine-induced myocarditis.
    Article CAS PubMed Google Scholar
  13. Hägg S, Spigset O, Bate A, Soderström TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol. 2001;21:382–8.
    Article PubMed Google Scholar
  14. Vesterby A, Pedersen JH, Kaempe B, Thomsen NJ. Sudden death during treatment with clozapine (Leponex). Ugeskr Laeger. 1980;142:170–1.
    CAS PubMed Google Scholar
  15. Reinders J, Parsonage W, Lange D et al. Clozapine related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Austr N Z J Psychiatry. 2004;38:915–22.
    Article Google Scholar
  16. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf. 2007;30:47–57.
    Article CAS PubMed Google Scholar
  17. Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: case series from the New Zealand Intensive Medicine Monitoring Programme. N Z Med J. 2008;121:68–74.
  18. Cohen D, Bogers JP, van Dijk D, et al. Beyond the white blood cell monitoring: screening the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73:1307–12.
  19. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841–5.
  20. Committee on Safety of Medicines. Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Probl Pharmacovigilance. 1993;19:9–10.
    Google Scholar
  21. Alawami M, Wasywich C, Cicovic A, Kenedi C. Systematic review of clozapine induced cardiomyopathy. Int J Cardiol. 2014;176:315–20.
    Article PubMed Google Scholar
  22. Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand. 2015;32:240–1.
    Article Google Scholar
  23. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res. 2011;128:161–5.
  24. Lang UE, Willbring M, von Golitschek R, et al. Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. J Psychopharmacol. 2008;22:576–80.
  25. Tan LH, Suetani S, Clark S, Wilson D. Late onset myocarditis with clozapine use. Aust N Z J Psychiatry. 2015;49:295.
    Article PubMed Google Scholar
  26. Jensen VE, Gøtzsche O. Allergic myocarditis in clozapine treatment. Ugeskr Laeger. 1994;156:4151–22.
    CAS PubMed Google Scholar
  27. Bandelow B, Degner D, Kreusch U, Rüther E. Myocarditis under therapy with clozapine. Schizophr Res. 1995;17:293–4.
    Article CAS PubMed Google Scholar
  28. Degner D, Bleich S, Grohmann R, et al. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry. 2000;34:880.
  29. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ. 2001;322:1207–9.
    Article CAS PubMed PubMed Central Google Scholar
  30. Kirpekar VC, Deshpande SM, Joshi PP. Reversible myocarditis in a patient receiving clozapine. Indian Heart J. 2001;53:779–81.
    CAS PubMed Google Scholar
  31. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001;345:224–5.
    Article PubMed Google Scholar
  32. Fineschi V, Neri M, Riezzo I, Turillazzi E. Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. Int J Legal Med. 2004;118:307–9.
  33. Pieroni M, Cavallaro R, Chimenti C, et al. Clozapine-induced hypersensitivity myocarditis. Chest. 2004;126:1703–5.
    Article PubMed Google Scholar
  34. Wehmeier PM, Heiser P, Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther. 2005;30:91–6.
  35. Merrill DB, Ahmari SE, Bradford JM, Lieberman JA. Myocarditis during clozapine treatment. Am J Psychiatry. 2006;163:204–8.
  36. Kakar P, Millar-Craig M, Kamaruddin H, et al. Clozapine induced myocarditis: a rare but fatal complication. Int J Cardiol. 2006;112:5–6.
    Article Google Scholar
  37. Razminia M, Salem Y, Devaki S, et al. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am J Ther. 2006;13:274–6.
    Article PubMed Google Scholar
  38. Annamraju S, Sheitman B, Saik S, Stephenson A. Early recognition of clozapine-induced myocarditis. J Clin Psychopharm. 2007;27:479–83.
  39. Varambally S, Howpage P. Acute myocarditis associated with clozapine. Australas Psychiatry. 2007;15:343–6.
    Article PubMed Google Scholar
  40. Caetano D, Gandhi C. Clozapine-induced myocarditis. Aust N Z J Psychiatry. 2008;42:434–5.
    PubMed Google Scholar
  41. Caetano D. Monitoring of clozapine-induced myocarditis. Australas psychiatry. 2009;17:421.
    Article PubMed Google Scholar
  42. Jayathilake I, Singh AK. Clozapine rechallenge after myocarditis. Australas Psychiatry. 2009;17:421–2.
    Article PubMed Google Scholar
  43. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: clinical update. Med J Aust. 2009;190:190–2.
  44. Ariyarajah V, Shaikh N, Garber PJ, et al. Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J Magn Reson Imaging. 2010;31:1473–6.
    Article PubMed Google Scholar
  45. Grgas M, Washburn CF Jr, Caley CF. Clozapine-induced myocarditis: 2 case reports. J Clin Psychopharmacol. 2010;30:91–2.
  46. Kamphuis H, Arends J, Timmerman L, et al. Myocarditis and cardiomyopathy: underestimated complications resulting from clozapine therapy. Tijdschr Psychiatr. 2010;52:223–33.
    CAS PubMed Google Scholar
  47. Ronaldson KJ, Taylor AJ, Fitzgerald PB, et al. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry. 2010;71:976–81.
    Article PubMed Google Scholar
  48. Rosenfeld AJ, Gibbs T, Ivie R, et al. Successful clozapine retrial after suspected myocarditis. Am J Psychiatry. 2010;167:350–1.
    Article PubMed Google Scholar
  49. Adamaszek M, Olbrich S, Hegerl U, Schönknecht P. Risk for myocarditis of clozapine and other atypical antipsychotics: case report and study of the literature. Psychiatr Prax. 2011;38:201–3.
  50. Bray A, Reid R. Successful clozapine rechallenge after acute myocarditis. Aust N Z J Psychiatry. 2011;45:90.
    Article PubMed Google Scholar
  51. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. New monitoring protocol for clozapine-induced myocarditis based on analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45:458–65.
  52. Albouaini K, Ruzsics B, Chenzbraun A. Multimodality cardiac imaging in clozapine-induced eosinophilic constrictive perimyocarditis. Eur Heart J Cardiovasc Imaging. 2012;14:338.
    Article PubMed Google Scholar
  53. De Berardis D, Serroni N, Campanella D, et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf. 2012;7:55–62.
  54. Ronaldson KJ, Fitzgerald PB, Taylor AJ, McNeil JJ. Continuation of clozapine following mild myocarditis. Australian and N Z J Psychiatry. 2012;46:910–1.
  55. Ronaldson KJ, Fitzgerald PB, Taylor AJ, McNeil JJ. Observation from 8 cases of clozapine rechallenge after development of myocarditis. J Clin Psychiatry. 2012;73:252–4.
    Article CAS PubMed Google Scholar
  56. Granja-Ingram NM, James J, Clark N, et al. Successful re-exposure to clozapine after eosinophilia and clinically suspected myocarditis. Rev Bras Psiquiatr. 2013;35:95–6.
    Article PubMed Google Scholar
  57. Ittasakul P, Archer A, Kezman J, et al. Rapid re-challenge with clozapine following pronounced myocarditis in a treatment-resistant schizophrenia patient. Clin Schizophr Relat Psychoses. 2013;18:1–11.
  58. Munshi T, Mazhar M, Hassan T. Clozapine reinitiation following a “red result” secondary to chemotherapy. Neuropsychiatr Dis Treat. 2013;9:1267–71.
    Article PubMed PubMed Central Google Scholar
  59. Nielsen J, Correll CU, Manu P, Kane JM. Termination of Clozapine treatment due to medical reasons: when is it warranted and how can be avoided? J Clin Psychiatry. 2013;74:603–13.
    Article CAS PubMed Google Scholar
  60. Chow V, Feijo I, Trieu J, et al. Successful rechallenge of clozapine therapy following previous clozapine-induced myocarditis confirmed on cardiac MRI. J Child Adolesc Psychopharmacol. 2014;24:99–101.
  61. Chow V, Yeoh T, Ng AC, et al. Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: multicentre cross-sectional cohort study. Open Heart. 2014;26(1):e000030. The first large study on clozapine subclinical cardiotoxicity.
    Article Google Scholar
  62. Kontoangelos K, Loizos S, Kanakakis J, et al. Myocarditis after administration of clozapine. Eur Rev Med Pharmacol Sci. 2014;18:2383–6.
  63. Munshi TA, Volochniouk D, Hassan T, Mazhar N. Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition? Case Rep Psychiatry. 2014;9:1267–71.
  64. Smith LT, Symons E, Hare JL, et al. Asymptomatic myocarditis during clozapine re-titration, in a patient who had previously been stable on clozapine for 10 years. Australas Psychiatry. 2014;22:539–42.
    Article PubMed Google Scholar
  65. Aboueid L, Toteja N. Clozapine-induced myocarditis: a case report of an adolescent boy with intellectual disability. Case Rep Psychiatry. 2015.
  66. Baptista T, Rojas N, Dávila DF. Heterogeneity of clozapine-associated myocarditis: an opportunity for novel preventing strategies. Aust N Z J Psychiatry. 2015;49:106.
    Article Google Scholar
  67. Cohen R, Lysenko A, Mallet T, et al. Case of clozapine-induced myocarditis in a young patient with bipolar disorder. Case Rep Cardiol. 2015;283156.
  68. de Leon J, Tang YL, Baptista T, et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatr Scand. 2015;132:242–3.
    Article PubMed Google Scholar
  69. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Evolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditis. Aust N Z J Psychiatry. 2015;49:486–7.
  70. Fehily SR, Forlano R, Fitzgerald PB. C-reactive protein: an early critical sign of clozapine-related myocarditis. Australas Psychiatry. 2015;24:181–4.
    Article PubMed Google Scholar
  71. Goodison G, Siskind D, Harcourt-Rigg C, et al. Clarifying the diagnosis of myocarditis in a patient on clozapine. Australas Psychiatry. 2015;23:311–3.
  72. Hatton JL, Bhat PK, Gandhi S. Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction. Tex Heart Inst J. 2015;42:155–7.
    Article PubMed PubMed Central Google Scholar
  73. Winckel K, Siskind D, Hollingworth S, Wheeler A. Clozapine-induced myocarditis: separating the wheat from the chaff. Aust N Z J Psychiatry. 2015;49:188.
  74. Ifteni P, Nielsen J, Burtea V et al. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand. 2014;130:25-29.
  75. Rostagno C, Domenichetti S, Pastorelli F, Gensini GF. Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. J Clin Psychopharmacol. 2011;31:712–6.
  76. From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc. 2001;86:1095–102.
    Article Google Scholar
  77. Rostagno C, Di Norscia G, Placidi GF, Gensini GF. Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry. 2008;30:280–3.
  78. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59:779–92.
    Article PubMed Google Scholar
  79. Reid P, McArthur M, Pridmore S. Clozapine rechallenge after myocarditis. Aust N Z J Psychiatry. 2001;35:249.
    Article CAS PubMed Google Scholar
  80. Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann Pharmacother. 1996;30:603–5.
    CAS PubMed Google Scholar
  81. Committee on Safety of Medicines. Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Probl Pharmacov. 1993;19:9–10.
    Google Scholar
  82. Youssef DL, Narayanan P, Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy in a regional mental health service in Australia. Australas Psychiatry. 2015.
  83. Phan KL, Taylor SF. Clozapine-associated cardiomyopathy. Psychosomatics. 2002;43:248.
    Article PubMed Google Scholar
  84. Kikuchi Y, Ataka K, Yagisawa K, et al. Clozapine-induced cardiomyopathy: first case in Japan. Schizophr Res. 2013;150:586–7.
    Article PubMed Google Scholar
  85. Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: a case/noncase study in the French Pharmacovigilance Database. Br J Clin Pharmacol. 2009;69:287–94.
  86. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry. 2004;38:915–22.
  87. Tanner MA, Culling W. Clozapine associated dilated cardiomyopathy. Postgrad Med J. 2003;79:412–3.
    Article CAS PubMed PubMed Central Google Scholar
  88. Makhoul B, Hochberg I, Rispler S, Azzam ZS. Dilated cardiomyopathy: an unusual complication of clozapine therapy. Nat Clin Pract Cardiovasc Med. 2008;5:566–70.
    Article CAS PubMed Google Scholar
  89. Bobb VT, Jarskog LF, Coffey BJ. Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine. J Child Adoles Psychopharmacol. 2010;20:539–43.
    Article Google Scholar
  90. Rostagno C, Domenichetti S, Pastorelli F, Gensini GF. Clozapine associated cardiomyopathy: cluster of 3 cases. Intern Emerg Med. 2011;6(3):281–3.
  91. Grubisha M, Gopalan P, Azzam PN. Takotsubo cardiomyopathy in a young man after maintenance electroconvulsive therapy and clozapine initiation: case report. J ECT. 2014;30:e40–1.
    Article PubMed Google Scholar
  92. Kropp S, Tountopoulou A, Schneider U, Lichtinghagen R. N-terminal fragment of B-type natriuretic peptide (NT-proBNP): a marker of cardiac safety during antipsychotic treatment. Ann General Psychiatry. 2005;4:10–5.
  93. Fontana PG, Sümegi, B. Association of Clozaril (clozapine) with cardiovascular toxicity. Dorval, Quebec: Novartis Pharmaceuticals Canada Inc.; 2002.
    Google Scholar
  94. Roh S, Ahn DH, Nam JH, et al. Cardiomyopathy associated with clozapine. Exp Clin Psychopharmacol. 2006;14:94–8.
    Article PubMed Google Scholar
  95. Tirupati S. Clozapine and heart in the Hunter Region. Aust N Z J Psychiatry. 2006;40:97.
    PubMed Google Scholar
  96. Floreani J, Bastiampillai T. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Aust N Z J Psychiatry. 2008;42:747–8.
    PubMed Google Scholar
  97. Pastor CA, Mehta M. Masked clozapine-induced cardiomyopathy. J Am Board Fam Med. 2008;21:70–4.
    Article PubMed Google Scholar
  98. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year-follow up of mortality in patients with schizophrenia: population-based cohort study (FIN11 study). Lancet. 2009;374:620–7.
    Article PubMed Google Scholar
  99. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671–7.
  100. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161–7.
    Article CAS PubMed Google Scholar
  101. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225–35.
    Article CAS PubMed PubMed Central Google Scholar
  102. Gerlach J, Jørgensen EO, Peacock L. Long-term experience with clozapine in Denmark: research and clinical practice. Psychoparmacology (Berl). 1989;99:92–6.
    Article Google Scholar
  103. Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000;61:441–6.
  104. Rostagno C, Domenichetti S, Gensini GF. Does a subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study. Cardiovasc Hematol Agents Med Chem. 2012;10:148–53. The first paper on clozapine subclinical cardiotoxicity.
    Article CAS PubMed Google Scholar
  105. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Clozapine-induced myocarditis and baseline echocardiography. Aust N Z J Psychiatry. 2012;46:1006–7.
    Article PubMed Google Scholar
  106. Ellis PM, Cameron CR. Clozapine-induced myocarditis and baseline echocardiograms. Aust N Z J Psychiatry. 2012;46:1005–6.
    Article PubMed Google Scholar
  107. Murch S, Tran N, Liew D, et al. Echocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experience. Austral Psychiatry. 2013;21:258–61.
    Article Google Scholar
  108. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114:3–13.
    Article CAS PubMed Google Scholar
  109. Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine, a retrospective cohort study. J Clin Psychiatry. 2010;71:304–11.
    Article CAS PubMed PubMed Central Google Scholar

Download references